Last reviewed · How we verify
NCT05608694
MRI Screening in Men at High Risk of Developing Prostate Cancer
NA trial testing Prostate MRI in Prostate Cancer Screening in 250 participants. Currently enrolling.
1 March 2037
Quick facts
| Lead sponsor | University of Chicago |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 250 |
| Start date | 2 March 2022 |
| Primary completion | 1 March 2037 |
| Estimated completion | 1 March 2039 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Prostate MRI
Conditions studied
- Prostate Cancer Screening — all drugs for Prostate Cancer Screening →
Sponsor
University of Chicago
Who can join
18 and older, male only, with Prostate Cancer Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether or not Magnetic Resonance Images (MRI) will identify high-grade cancers earlier and more frequently in men at high risk of developing prostate cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.
Cheng HH, Shevach JW, Castro E, Couch FJ, et al · · 2024 · cited 30× · PMID 39052257 · DOI 10.1001/jamaoncol.2024.2185
Verify or expand the search:
- PubMed search for NCT05608694
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Prostate MRI
Trials testing the same drug.
- NCT05903781 — Value of Ultra-fast Prostate MRI in Prostate Cancer · completed
Other recruiting trials for Prostate Cancer Screening
Currently open trials in the same condition.
- NCT06626022 — Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging. · Phase 3 · recruiting
- NCT06923657 — PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy · NA · recruiting
Other University of Chicago trials
Trials by the same sponsor.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
- NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
- NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
- NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05608694 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chicago
- Last refreshed: 2 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05608694.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing